Decreased expression of tumor necrosis factor family receptors involved in humoral immune responses in preterm neonates

Blood

Volumn 110, Issue 8, 2007, Pages 2948-2954

  Kaur, Kulwant ^a,b   Chowdhury, Shimul ^a,b   Greenspan, Neil S ^c   Schreiber, John R ^a,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b University of Minnesota Children's Hospital   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; B CELL MATURATION ANTIGEN; B LYMPHOCYTE ACTIVATING FACTOR RECEPTOR; B7 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; FC RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 10; RECOMBINANT PROTEIN; TRANSMEMBRANE ACTIVATOR CALCIUM MODULATOR AND CYCLOPHILIN LIGAND INTERACTING PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL INTERACTION; COMPARATIVE STUDY; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGLOBULIN PRODUCTION; LYMPHOCYTE PROLIFERATION; NEWBORN; NORMAL HUMAN; PREMATURITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PROCESSING; T LYMPHOCYTE; TERM BIRTH; UMBILICAL CORD BLOOD;

EID: 35548967182     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-01-069245     Document Type: Article

References (46)

1. Lewis DB, Wilson CB. Developmental immunology and the role of host defenses in fetal and neonatal susceptibility to infection. In: Remington JS, Klein JO, eds. Infectious Diseases in Fetus and Newborn. Philadelphia, PA: WB Saunders, 2001:25-138.
2. Fanaroff AA, Korones SB, Wright LL, et al. The incidence, presenting features, risk factors, and significance of septicemia in low birth weight infants. The National Institute of Child Health and Human Developmental Neonatal Research Network. Pediatr Infect Dis J 1998;17:593-598.
3. Stoll BJ, Hansen N. Infections in VLBW infants: studies from the NICHD neonatal research network. Seminars in Perinatol. 2003;27:293-301.
4. Kurikka S, Kayhty H, Peltola H, Saarinen L, Eskola J, Makela PH. Neonatal immunization: response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. Pediatrics. 1995;95:815-822.
5. Black SB, Shinefield HR, Fireman B, Hiatt R, Polen M, Vittinghoff E. Efficacy in infancy of oligosaccharide Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J. 1991;10:97-104.
6. Khalak R, Pichichero ME, D'Angio CT. Three-year follow-up of vaccine response in extreme-ly preterm infants. Pediatrics. 1998;101:597-603.
7. Kristensen K, Gyhrs A, Lausen B, Barrington T, Heilmann C. Antibody response to Haemophilus influenzae type b capsular polysaccharide conjugated to tetanus toxoid in preterm infants. Pediatr Infect Dis J. 1996;15:525-529.
8. Heath PT, Booy R, McVernon J, et al. Hib vaccination in infants born prematurely. Arch Dis Child. 2003;88:206-210.
9. Slack MH, Schapira D, Thwaites RJ, et al. Immune response of premature infants to meningococcal serogroups C and combined diphtheriatetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines. J Infect Dis. 2001;184:1617-1620.
10. Munoz A, Salvador A, Brodsky NL, Arbeter AM, Porat R. Antibody response of low birth weight infants to Haemophilus influenzae type b polyribosylribitol phosphate-outer membrane protein conjugate vaccine. Pediatrics. 1995;96:216-219.
11. McVernon J, Johnson PD, Pollard AJ, Slack MP, Moxon ER. Immunologic memory in Haemophilus influenzae type b vaccine failure. Arch Dis Child. 2003;88:379-383.
12. Shinefield H, Black S, Ray P, Fireman B, Schwalbe J, Lewis E. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J. 2002;21:182-186.
13. Bishop GA, Hostager BS. Signaling by CD40 and its mimics in B cell activation. Immunol Res. 2001;24:97-109.
14. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol. 2002;2:465-475.
15. Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2003;21:231-264.
16. Thompson JS, Bixler SA, Qian F, et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 2001;293:2108-2111.
17. van Kooten C, Banchereau J. Functional role of CD40 and its ligand. Int Arch Allergy Immunol. 1997;113:393-399.
18. Lipsky P, Attrep JF, Grammer AC, McIlraith MJ, Nishioka Y. Analysis of CD40-CD40 ligand interactions in the regulation of human B cell function. Ann N Y Acad Sci. 1997;815:372-383.
19. Guttormsen HK, Sharpe AH, Chandraker AK, Brigtsen AK, Sayegh MH, Kasper DL. Cognate stimulatory B-cell-T-cell interactions are critical for T cell help recruited by glycoconjugate vaccines. Infect Immun. 1999;67:6375-84.
20. Nonoyama S, Penix LA, Edwards CP, et al. Diminished expression of CD40 ligand by activated neonatal T cells. J Clin Invest. 1995;95:66-75.
21. Splawski JB, Nishioka J, Nishioka Y, Lipsky PE. CD40 ligand is expressed and functional on activated neonatal T cells. J Immunol. 1996;156:119-127.
22. Min B, Legge KL, Bell JJ, et al. Neonatal exposure to antigen induces defective CD40 ligand expression that undermines both IL-12 production by APC and IL-2 receptor up-regulation on splenic T cells and perpetuates IFN-gamma-dependent T cell anergy. J Immunol. 2001;166:5594-5603.
23. Han P, McDonald T, Hodge G. Potential immaturity of the T cell and antigen presenting cell interaction in cord blood with particular emphasis on the CD40-CD40 ligand costimulatory pathway. Immunology. 2004;113:26-34.
24. Wu ZQ, Vos Q, Shen Y, et al. In vivo polysaccharide specific IgG isotype responses to intact Streptococcus pneumoniae are T cell dependent and require CD40- and B7-ligand interactions. J Immunol. 1999;163:659-667.
25. Wu ZQ, Khan A, Shen Y, et al. B7 requirements for primary and secondary protein and polysaccharide specific Ig isotype responses to Streptococcus pneumoniae. J Immunol. 2000;165:6840-6848.
26. Ng LG, Sutherland AP, Newton R, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol. 2004;173:807-817.
27. Craxton A, Magaletti D, Ryan EJ, Clark EA. Macrophage-and dendritic cell-dependent regulation of human B cell proliferation requires the TNF family ligand BAFF. Blood. 2003;101:4464-4471.
28. Castigli E, Scott S, Dedoglu F, et al. Impaired class switching in APRIL-deficient mice. Proc Natl Acad Sci U S A. 2004;16:3903-3908.
29. Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189:1747-1756.
30. Batten M, Groom J, Cachero TG, et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med. 2000;192:1453-1466.
31. Castigli E, Wilson SA, Garibyan L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet. 2005;37:829-834.
32. von Bulow GU, van Deursen JM, Bram RJ. Regulation of the T-independent humoral response by TACI. Immunity. 2001;14:573-582.
33. 197 conjugate vaccine occurs despite vigorous T cell help induced by the carrier protein. J Infect Dis. 2003;187:1629-1638.
34. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol. 2000;25:169-193.
35. Suzuki K, Meek B, Doi Y, et al. Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. Proc Natl Acad Sci U S A. 2004;101:1981-1986.
36. McLay J, Leonard E, Petersen S, Shapiro D, Greenspan N, Schreiber J. Gamma 3 gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides, II: increased susceptibility to fatal pneumococcal sepsis due to absence of antipolysaccharide IgG3 is corrected by induction of anti-polysaccharide IgG1. J Immunol. 2002;168:3437-43.
37. Rosner B. Fundamentals of Biostatistics. 4th ed. Belmont, CA: Duxbury Press; 1995.
38. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York, NY: Springer; 2000.
39. Agematsu K, Hokibara S, Nagumo H, Komiyama A. CD27: a memory B-cell marker. Immunol Today. 2000;21:204-206.
40. Maurer D, Holter W, Majdic O, Ficher GF, Knapp W. CD27 expression by a distinct subpopulation of human B lymphocytes. Eur J Immunol. 1990;20:2679-2684.
41. Lenschow DJ, Sperling AI, Cooke MP, et al. Differential upregulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. J Immunol. 1994;153:1990-1997.
42. Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med. 1994;180:631-640.
43. Castigli E, Wilson SA, Scott S, et al. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med. 2005;201:35-39.
44. Salzer U, Chapel HM, Webster AD, et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet. 2005;37:820-828.
45. Gathings WEH, Kubagawa H, Cooper MD. A distinctive pattern of B cell immaturity in perinatal humans. Immunol Rev. 1981;57:107-126.
46. Matthews NC, Wadhwa M, Bird C, et al. Sustained expression of CD154 (CD40L) and proinflammatory cytokine production by alloantigenstimulated umbilical cord blood T cell. J Immunol. 2000;164:6206-6212.